Initially, cholinergic therapy for AD was directed toward inhibition of acetylcholinesterase (AChE, EC 3.1.1.7) as the main enzyme that hydrolyzes the neurotransmitter acetylcholine [5]. This evidence concerns the gene ACHE and Alzheimer disease.